Abstract 54-year-old gentleman with a previous medical history characterized by recurrent bi-frontal and bi-temporal headaches, mild hypertension, hypercholesterolemia and recurrent renal calculi.
Approximately three weeks after, he was admitted to the stroke ward after developing an acute onset of right brachial-facial paresis (4/5), bilateral blurred vision, bi-frontal headache and dizziness. The head CT on admission did not show signs of ischemia or haemorrhage, and the CTA showed a small amount of mixed plaque with the bifurcations, without flow disturbances. An MRI done 5 days after revealed a moderate sized recent left-sided pontine infarct and a well-delineated right corpus callosum and centrum semiovale infarcts (Figure 2A ,B,C and D). These multi-territory ischemic events were suggestive of a cardio-embolic source and this prompted a 24-hour tape that revealed RBBB, aberrant conduction triplets, rare ventricular couplets, yet no atrial fibrillation. Four days after, a cardiac MRI was performed showing a dilated left ventricle (LV) mildly hypertrophic and dyssynchronous with global hypokinesia and overall systolic impairment (LVEF 43%); no intramural thrombus was identified. No obvious source of intra-cardiac source of emboli was demonstrated. Following a cardiological review, he was started on warfarin for a possible diagnosis of non-AF-related cardio-embolisms associated with DCMP and poor LEVF. He was then discharged with warfarin, prednisolone (60 mg/day), spironolactone, losartan, bisoprolol and atorvastatin. Journal of Case Reports and Studies During the following month, he was admitted on two occasions for acute episodes of shortness of breath associated with lower tract infections, treated with seven-day courses of antibiotics, with good resolution.
Following a review by the consultant rheumatologist, he began to gradually reduce the dose of prednisolone to 20 mg/day during the subsequent 2 months. He also underwent a second head MRI as an outpatient revealing a on-going resolution of his previous ischemic events ( Figure 3A and B); more so, as seen in on the axial T1-post contrast cut (Figure 4 ), there was a subtle enhancement in the left M1 segment of the MCA. Due to rather rapid resolution of the ischemic images, a lumbar puncture was done to rule out the presence of oligoclonal bands. There were no oligoclonal bands (OCB); there was a slight increase in opening pressure, mildly raised proteins and white cell count, with normal glucose. A full set of blood investigations including antibodies for systemic vasculitis (ANCA-p, ANCA-c, MPO, ANA, Anti-Jo1), infectious diseases (HIV, HVB, HVC, HSV1/HSV/2, VZ, enterovirus), and thrombophilia (and other coagulation disorders) revealed also to be negative. Due to the persistence of headaches associated with blurred vision, generalized aches, new-onset right upper limb apraxia, another MRI was done showing areas of sub acute infarctions in the head of the right caudate nucleus, the posterior limb of the left internal capsule ( Figure 5A and B) and a new infarction in the right parietal lobe, which showed restricted diffusion in keeping with an acute event. Interestingly, these new strokes occurred as the dose of steroids was reduced. One month later, a final MRI was done, showing yet again, another stroke located in the left superior temporal gyrus ( Figure 6A and B). A CT of the chest, abdomen and pelvis was also done without any signs of malignancy or systemic disease.
At this point, the diagnosis of a primary central nervous system angiitis was seriously considered. Hence, a new CTA was requested revealing, very interestingly, an obvious reduction in the diameter of both left and right MCAs ( Figure 7A ,B,C and D). Two days later, a Digital Subtraction Angiography (DSA) was performed, confirming the narrowing of both MCAs ( Figure 8A ,B and C). In view of the most recent CTA and DSA, it was felt that I biopsy was no longer required to diagnosis this patient with a primary central nervous system angiitis. Unfortunately, one day before the DSA, he presented with a worsening of right upper limb weakness associated with moderate dysarthria and mild confusion. In view of the very rapid and aggressive clinical progression, the patient was started on intravenous methylprednisolone and cyclophosphamide with the objective of controlling the inflammatory process. Nevertheless, despite being on optimal treatment, he developed soon after an extensive -malignant -left MCA infarction, which required decompressive hemicraniectomy ( Figure 9A and B).
Currently, he remains globally aphasic with mild right facio-brachial paresis (3/5) and ipsilateral hypoesthesia. He also continues to receive daily steroids and immunomodulators, from which he appears to be tolerating well.
Once more stable, he underwent cardiological studies such as a heart MRI, which did not reveal any signs of vasculitis.
He continues to be evaluated by a multidisciplinary team, including neurologist, stroke physicians, rheumatologist and occupational therapists, speech and language therapist and physiotherapists.
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Treatment
Combined immunosuppressive therapy is the treatment of choice for PACNS. This therapy, after being successful in cases of systemic vascultitis such as Wegener's granulomatosis and polyarteritis nodosa, was further proposed as a plausible treatment for PACNS. However, it has not been supported by any randomized controlled trial (RCT) yet.
The current recommendation is prednisone, 1 mg/kg/day and cyclophosphamide (CYC), 2 mg/kg/day. The treatment consists of two phases: induction of remission and maintenance of remission. The duration of treatment for each phase is still debatable, however, most specialized centres use prednisolone and cyclophosphamide for 4-6 months to induce clinical remission, and then taper prednisolone off to continue cyclophosphamide for 1 year.
Another alternative of treatment has been proposed by Joseph and Scolding (Practical Neurology 2002): (A) Induction regimen for 9-12 weeks: cyclophosphamide 2.5 mg/kg/day coupled with IV-Methylprednisolone, 1 gr/day for 3 days, then oral prednisolone, 60 mg/day, to be decreased by 10 mg at weekly intervals to reach a dose of 10 mg/day, if possible and, (B) maintenance regimen for further 10 months: alternate day steroids (10-20 mg prednisolone) along with azathioprine, 2 mg/kg/day, substituted for cyclophosphamide.
Intravenous immunoglobulin (IVIG), plasmapheresis, and monoclonal antibodies have not been used extensively in PACNS and therefore data with regards to these options are not optimal.
Finally, a calorie-controlled and sodium controlled diet should be advised for patients who are on long-term steroids. Furthermore, these patients should also be advised on taking vitamin D and calcium supplements.
Discussion
Primary angiitis of the CNS (PACNS) is a very rare disorder, with approximately 700 cases published worldwide [1] . It offers unique and unusual problems for the neurologist.
Its wide variety of non-specific, intermittent and recurrent signs and symptoms, which do not resemble any specific clinical pattern is particularly challenging. More so, there are no serological or spinal fluid laboratory tests of any sensitivity or specificity. Furthermore, imaging by CT or MRI is likewise wholly lacking in sensitivity. And finally, Digital Subtraction Angiography (DSA) results may be overestimated. Therefore, when encountering a possible case of PACNS, it is only through an appropriate chronological description of the clinical presentation coupled with suggestive imaging results that provide the most powerful and sensitive diagnostic tool. The lack of one solid 'pathognomonic' indicator of disease makes a holistic approach that much important.
In 1988, Calabrese and Mallek [2] proposed criteria for the diagnosis of PACNS: the presence of an acquired and otherwise unexplained neurological deficit with (1) the presence of either classic angiographic or histopathologic features of angiitis within the CNS and (2) no evidence of systemic vasculitis or any condition that could elicit the angiographic or pathologic features.
Clinically, the most common symptom is headache (70-90%), followed by cognitive or behavior changes (roughly 50%), focal weakness (38-40%) and visual symptoms (18-20%). Other symptoms may include posterior fossa symptoms and myelopathy (the later is a rare clinical condition in PACNS). Within the cognitive manifestations, confusion is by far the most common presentation, occurring in almost 40% of patients. On the other hand, with regards to focal weakness, hemiparesis tends to affect around 60% of patients during some stage of their disease (paraparesis and monoparesis being the second most common motor deficiency). Our patient presented a constellation of symptoms, mainly headaches, blurred vision, intermittent focal weakness and emotional variability.
In terms of radiological images, MRI scans prove to be highly sensitive (100%), but low in specificity. Much like the clinical presentation -, which can be highly variable, non-specific and common to many other conditions -the MRI findings are equally Methotrexate, 10-25 mg weekly, might be used in case of cyclophosphamide or azathioprine toxicity. Although no prospective controlled studies have been performed on this treatment, retrospective analysis shows positive results and good evidence to continue its use.
